Tarsus Pharmaceuticals, Inc. (TARS) Stock
TARS has an Alpha Score of 35 out of 100 (weak), computed on Nov 4, 2026 from 2 of 4 sub-scores. 5 of the hedge funds AlphaScala tracks reported TARS in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Millennium Management's at $89.82M. Company insiders reported 0 open-market buys and 14 sales on SEC Form 4 in the 90 days to Nov 9, 2026.
What is TARS's Alpha Score?
How it works →Alpha Score of 35 reflects weak overall profile with weak momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own TARS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.43M | $89.82M | +153% |
| D.E. Shaw David Shaw | 711K | $44.72M | -10% |
| Citadel Ken Griffin | 242K | $15.21M | +47% |
| Hussman Investment Trust John Hussman | 42K | $3.30M | +100% |
| Renaissance Technologies Jim Simons (founder) | 9K | $585.3K | -87% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Tarsus Pharmaceuticals, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 15, 26 | Link William J Phd | Director | SELL | 11.7K | $915K |
| Sep 15, 26 | Link William J Phd | Director | SELL | 759 | $60K |
| Sep 15, 26 | Link William J Phd | Director | SELL | 66 | $5K |
| Sep 4, 26 | Neervannan Seshadri | Chief Operating Officer | SELL | 4.6K | $388K |
| Sep 4, 26 | Azamian Bobak R. | President/CEO and Board Chair | SELL | 7.1K | $641K |
| Sep 4, 26 | Azamian Bobak R. | President/CEO and Board Chair | SELL | 2.9K | $265K |
| Sep 4, 26 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 5.4K | $458K |
| Sep 4, 26 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 5.4K | $485K |
| Sep 4, 26 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 1.6K | $135K |
| Sep 4, 26 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 1.6K | $143K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are TARS's key statistics?
Key statistics as of Nov 4, 2026
How does TARS's valuation compare with the Healthcare sector?
| Metric | TARS | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -7.67% | 3.62% | 174 |
| Return on equity | -13.53% | 2.96% | 200 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
TARS price chart
Powered by TradingViewWhat does Tarsus Pharmaceuticals, Inc. do?
Tarsus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for the treatment of ophthalmic conditions. The company’s primary focus is on innovative treatments that address significant unmet medical needs in eye care, particularly in diseases affecting the anterior segment of the eye. Central to its portfolio is a targeted, investigational compound aimed at treating Demodex blepharitis, a common eyelid condition. Tarsus leverages advanced diagnostic tools and delivery mechanisms to enhance the efficacy and safety of its therapeutic candidates. Positioned within the dynamic biopharmaceutical industry, Tarsus Pharmaceuticals supports healthcare innovation by bridging gaps in available ophthalmic therapies. By prioritizing both patient outcomes and physician needs, the company plays a crucial role in the medical field, pushing boundaries in drug development and offering potential transformative solutions for eye health. Headquartered in Irvine, California, Tarsus continues to collaborate with researchers and clinical experts to advance its robust pipeline, reinforcing its commitment to addressing diverse ophthalmological challenges worldwide.